Anti-Glycan Antibodies in the Diagnosis of Gastric Cancer

Шилова, Н. В.; Polyakova, Svetlana; Lipatnikov, Alexander; Navakouski, Maksim; Bovin, Nicolai V.; Никулин, М П; Tupitsyn, Nicolai

doi:10.1016/j.htct.2021.10.978

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The deficiency increased with age ( Table 1 and Figure 1 ). The low level of anti-Man IgM in patients with GC confirms our earlier report 20 and is consistent with other data pertaining to innate immunity deficiency associated with D-Man (MR, and in some cases MBL as a part of innate immunity).…”

Section: The Role Of Mannose In Gastric Cancer Progressionsupporting

confidence: 92%

Innate IgM antibodies to mannose in patients with gastric cancer

Nikulin,

Shilova,

Lipatnikov

et al. 2023

Cancer Biol Med

View full text Add to dashboard Cite

Section: The Role Of Mannose In Gastric Cancer Progressionsupporting

confidence: 92%

Innate IgM antibodies to mannose in patients with gastric cancer

Nikulin,

Shilova,

Lipatnikov

et al. 2023

Cancer Biol Med

View full text Add to dashboard Cite

“…A recent study from Shilova et al exemplified the potential of such glycan makers. 252 Sera from gastric cancer patients ( n = 146) and healthy controls ( n = 55) were compared on a 300-component glycan array, which identified a signature of IgM to seven targets and IgG to four targets (including both IgM and IgG against TF) that correctly diagnosed 81% of cases. As discussed in Section 4.1, glycan microarray screening has also been used to identify distinct serum antibody binding profiles in patients with H. pylori infection compared to uninfected individuals.…”

Section: Cancermentioning

confidence: 99%

Serum antibody screening using glycan arrays

Marglous,

Brown,

Padler-Karavani

et al. 2024

Chem. Soc. Rev.

View full text Add to dashboard Cite

show abstract

“…Многие из этих антител направлены к гликанам [29], в том числе и к опухолеассоциированным Тn, TF, SiaTn, которые в избытке экспрессируются на опухолях желудочно-кишечного тракта [30]. Ранее нами были изучены профили антигликановых антител на представительной когорте из групп доноров и больных РЖ с помощью PGA (printed glycan array) [31]. Среди прочего обнаружено, что значимая разница между группами наблюдается по антителам класса М, направленным к производному αMan-R (R = NHCOCH 2 NH; p = 0,0038), и антителам, направленным к дисахариду Mana1-6Manβ (p = 0,0033).…”

Section: антигликановые антителаunclassified

“…В нашей работе у больных РЖ мы выявили дефицит антигликановых антител к Manβ и Manβ1-4GlcNAcβкоровым фрагментам N-цепей гликопротеинов, причем с возрастом дефицит нарастал. Такие гликаны, [31,33], а также согласу ется с данными других исследователей о дефиците врожденного звена иммунитета, связанного с маннозой, при этой патологии [26].…”

Section: заключениеunclassified

Mannose antibody levels in gastric cancer patients (literature review and clinical and experimental study)

Nikulin,

Shilova,

Lipatnikov

et al. 2023

Rossijskij bioterapevtičeskij žurnal

View full text Add to dashboard Cite

Introduction. Glycans play an important role in the pathogenesis of malignant neoplasms, including stomach cancer. In recent years, the attention of many researchers has been drawn to mannose (Man) – hexose, which is an indispensable component of all N-chains of glycoproteins involved in both normal physiological and pathological processes.Aim. To investigate the role of innate immunity factors and ways to influence them through mannose and mannose-containing glycans in gastric cancer patients. Materials and methods. Data on the role of mannose – one of the key monosaccharides in the formation of glycoprotein N-chains – and its binding receptors (mannose receptor, mannose-binding lectin, antibodies) in gastric cancer since 2006 are presented. Levels of anti-glycan antibodies in blood serum samples of 235 gastric cancer patients and 76 healthy donors were evaluated using a glycochip.Results. It has been shown that the level of IgM-class antibodies to Manβ – the core part of N-glycans – in gastric cancer patients is significantly lower compared to the donor group, regardless of age (p = 0.0001). To assess the effect of age on the levels of antiglycan antibodies, patients were divided into two subgroups – before and after 45 years. In the group under 45 years of age, significant differences in the levels of antiglycan antibodies to Manβ persisted, while significant differences in the levels of antiglycan antibodies to Manβ1-4GlcNAcβ were not observed. when comparing groups of patients and donors older than 45 years, the levels of antibodies to Manβ and Manβ1-4GlcNAcβ were significantly higher only in donors. Conclusion. Deficiency of humoral immunity may be one of the key factors in the initiation and progression of carcinogenesis in humans. In our work, in patients with stomach cancer, we revealed a deficiency of antiglycan antibodies to Manβ and to Manβ1-4GlcNAcβ – core fragments of N-chains of glycoproteins, and the deficiency increased with age. The results of the study are a promising platform for further research aimed not only at studying the role of anti-mannose antibodies, but also at developing approaches to adoptive immunoprophylaxis.

show abstract

Anti-Glycan Antibodies in the Diagnosis of Gastric Cancer

Cited by 3 publications

References 0 publications

Innate IgM antibodies to mannose in patients with gastric cancer

Innate IgM antibodies to mannose in patients with gastric cancer

Serum antibody screening using glycan arrays

Mannose antibody levels in gastric cancer patients (literature review and clinical and experimental study)

Contact Info

Product

Resources

About